Delving into the Latest Updates on D2M Biotherapeutics (Suzhou) Ltd. with Synapse

Overview

Basic Info

Introduction

D2M Biotherapeutics (Suzhou) Ltd., established in the year 2020, was co-founded by the former Senior Director of Human Genetics Target Sciences at Pfizer Dr. Nan Bing, in collaboration with Dr. Dong Zhang, who previously served as the Director of Oncology Immunology at Merck Germany. D2M Biosciences aims to leverage its proprietary genomic data analysis platform to identify highly reliable novel targets and to engineer high-quality therapeutic molecules. By achieving continuous innovation at the source, the company strives to increase the rate of clinical success and bring safer and more effective treatment options to patients expeditiously.

Tags

Immune System Diseases

Neoplasms

Skin and Musculoskeletal Diseases

Antibody

Bispecific antibody

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Immune System Diseases	2
Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Antibody	3
Bispecific antibody	2
Antibody drug conjugate (ADC)	1
Monoclonal antibody	1

Top 5 Target	Count

LILRB1 x LILRB2	2
MICA x MICB	1

The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors
The main questions it aims to answer are:
What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab??
Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.

Start Date01 Mar 2024

Sponsor / Collaborator

D2M Biotherapeutics (Suzhou) Ltd.

CTR20241486 / Not yet recruitingPhase 1

一项评估DM919（一种新型抗MICA/B抗体）单药治疗以及与帕博利珠单抗联合治疗晚期实体瘤受试者的首次人体、开放性、Ia/Ib期剂量递增和扩展队列研究

[Translation] A first-in-human, open-label, Phase Ia/Ib dose-escalation and expansion cohort study evaluating DM919, a novel anti-MICA/B antibody, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors

本研究是一项DM919治疗晚期实体瘤受试者的开放性、首次人体（FIH）I期研究。研究设计包括剂量递增阶段和剂量扩展阶段，旨在表征DM919单药治疗晚期实体瘤成人受试者的安全性、耐受性和活性，并确定扩展队列推荐剂量（RDE）和II期推荐剂量（RP2D）。在剂量递增阶段，晚期实体瘤受试者将接受剂量递增的DM919单药治疗（以确定RDE）。在研究的剂量扩展部分中，将对选定类型的实体瘤受试者进行治疗，以确定RP2D。

[Translation]

This study is an open-label, first-in-human (FIH) Phase I study of DM919 in the treatment of subjects with advanced solid tumors. The study design includes a dose escalation phase and a dose expansion phase, which aims to characterize the safety, tolerability and activity of DM919 monotherapy in adult subjects with advanced solid tumors, and to determine the recommended dose (RDE) for the expansion cohort and the recommended dose (RP2D) for Phase II. In the dose escalation phase, subjects with advanced solid tumors will receive escalating doses of DM919 monotherapy (to determine the RDE). In the dose expansion portion of the study, subjects with selected types of solid tumors will be treated to determine the RP2D.

Start Date-

Sponsor / Collaborator

D2M Biotherapeutics (Suzhou) Ltd.

100 Clinical Results associated with D2M Biotherapeutics (Suzhou) Ltd.

Login to view more data

0 Patents (Medical) associated with D2M Biotherapeutics (Suzhou) Ltd.

Login to view more data

100 Deals associated with D2M Biotherapeutics (Suzhou) Ltd.

Login to view more data

100 Translational Medicine associated with D2M Biotherapeutics (Suzhou) Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DM-919 ( MICA x MICB )	Advanced Malignant Solid Neoplasm More	Phase 1
D2M-006	Diabetes Mellitus, Type 1 More	Preclinical
D2M-008	Primary Biliary Cholangitis More	Preclinical
DM-926 ( LILRB1 x LILRB2 )	Neoplasms More	Preclinical
DM002 ( LILRB1 x LILRB2 )	Neoplasms More	Preclinical